BT11 is an orally active compound that binds to lanthionine synthetase C-like 2 (LANCL2) with a Kd value of 7.7 μM and can be used for the treatment of inflammatory bowel disease.
in vivo
Oral administration of 8 mg/kg/day BT-11 to mice attenuates colitis. In the drug safety testing experiment in rats, oral high concentrations of BT-11 have good safety (detection concentration up to 1000 mg/kg/day).
